Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Current Assets (2023 - 2025)

CG Oncology (CGON) has disclosed Current Assets for 3 consecutive years, with $759.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 0.7% year-over-year to $759.5 million, compared with a TTM value of $759.5 million through Dec 2025, up 0.7%, and an annual FY2025 reading of $759.5 million, up 0.7% over the prior year.
  • Current Assets was $759.5 million for Q4 2025 at CG Oncology, up from $695.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $759.5 million in Q4 2025 and bottomed at $194.1 million in Q4 2023.
  • Average Current Assets over 3 years is $608.0 million, with a median of $673.0 million recorded in 2025.
  • The sharpest move saw Current Assets surged 288.52% in 2024, then rose 0.7% in 2025.
  • Year by year, Current Assets stood at $194.1 million in 2023, then soared by 288.52% to $754.2 million in 2024, then rose by 0.7% to $759.5 million in 2025.
  • Business Quant data shows Current Assets for CGON at $759.5 million in Q4 2025, $695.8 million in Q3 2025, and $673.0 million in Q2 2025.